FDA naming proposal would decrease competition, FTC says

The staffs of three Federal Trade Commission offices argue that a Food and Drug Administration proposal on naming certain biological products could cause decreased price competition.

The FDA is proposing that...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@ftcwatch.com

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch